Leuprorelin oral - Enteris BioPharma

Drug Profile

Leuprorelin oral - Enteris BioPharma

Alternative Names: Leuprolide acetate oral - Enteris BioPharma; Ovarest™

Latest Information Update: 27 Jun 2016

Price : $50

At a glance

  • Originator Unigene Laboratories
  • Developer Enteris BioPharma; Unigene Laboratories
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Endometriosis
  • Discontinued Precocious puberty; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 14 Jun 2016 Enteris BioPharma plans a phase IIa trial for Endometriosis (In healthy volunteers) in USA and Canada (PO) (NCT02807363)
  • 15 Mar 2016 Biomarkers information updated
  • 04 Apr 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top